CJEU hands down SPC guidance in Royalty Pharma

The Court of Justice of the European Union (CJEU) has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates (SPCs).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

SPCs: a deep dive into CJEU case law

23 June 2020 The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.

Big Pharma

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

15 May 2020 The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

Big Pharma

CJEU puts further brakes on SPCs

22 March 2019 The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

CJEU hands down SPC guidance in Royalty Pharma

More on this story

Editor's picks

Editor's picks

More features